HCTI
NASD Healthcare Triangle, Inc.$0.7250 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.7250, $0.0095 below the day’s high of $0.7345
- YTD change
- -98.09%
- vs 20-day SMA
- -4.59%
- vs 200-day SMA
- -92.79%
Price ranges
Price & Performance
-1.69 (-70.04%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $2,610.0000
- HCTI is down 98% since the beginning of the year
- HCTI is down 100% over the past 12 months
- HCTI is down 12% over the past 1 month
- 20% of all HCTI investors are betting against HCTI
HCTI reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -72.8%.
- Previous minute
- +$0.0098
- Last hour
- -$0.0326
- Last 5 days
- -0.66%
- vs 8-day SMA
- -5.14%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Healthcare Triangle, Inc. operates as a healthcare information technology company, which engages in advancing various solutions for the cloud services, data science, and professional and managed services sectors for the healthcare and life sciences industry. It operates through the following segments: Software Services, Managed Services and Support, and Platform Services. The Software Services segment focuses on the sale of software services that are generated from providing strategic advisory, implementation, and development services. The Managed Services and Support segment includes post implementation support and cloud hosting. The Platform services segment offers solutions under CloudEz, DataEz, and Readabl.AI. The company was founded by Suresh Venkatachari and Keith T. Ryan on October 29, 2019 and is headquartered in Pleasanton, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.